Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial.

Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind,... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Immunopharmacology Pubmed

Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial.

Loading next page...
 
/lp/pubmed/sirolimus-as-a-new-drug-to-treat-rif-patients-with-elevated-th17-treg-zryEJ43ywP

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1567-5769
DOI
10.1016/j.intimp.2019.105730
pmid
31299610

Abstract

Journal

International ImmunopharmacologyPubmed

Published: Feb 17, 2020

There are no references for this article.